Pamela Huhn, NP
Family · Zanesville, OHNPI 1750750477
Payments from drug & device makers
Across 337 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$654
- AstraZeneca$618
- Mallinckrodt Hospital Products Inc.$591
- ANI Pharmaceuticals, Inc.$502
- Amgen$327
- Otsuka America Pharmaceutical, Inc.$320
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,27696%
- Education$2424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 50 | $654 |
| AstraZeneca(2 entities) | 32 | $618 |
| Mallinckrodt Hospital Products Inc. | 34 | $591 |
| ANI Pharmaceuticals, Inc. | 34 | $502 |
| Amgen | 18 | $327 |
| Otsuka America Pharmaceutical, Inc. | 16 | $320 |
| Fresenius USA Marketing, Inc. | 16 | $268 |
| Calliditas Therapeutics US Inc. | 10 | $241 |
| Daiichi Sankyo Inc. | 14 | $217 |
| Novartis | 10 | $197 |
| OPKO Pharmaceuticals, LLC | 9 | $151 |
| Novo Nordisk | 8 | $144 |
| Akebia Therapeutics Inc | 8 | $144 |
| GSK | 9 | $138 |
| Travere Therapeutics, Inc. | 17 | $130 |
| Aurinia Pharma U.S., Inc. | 6 | $97 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $97 |
| Boehringer Ingelheim | 5 | $86 |
| Ardelyx, Inc. | 5 | $85 |
| Nestle Healthcare Nutrition Inc. | 4 | $68 |
| Vifor Pharma, Inc. | 3 | $47 |
| Alnylam Pharmaceuticals Inc. | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Renalytix AI, Inc. | 3 | $42 |
| AbbVie | 2 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Baxter Healthcare | 2 | $30 |
| Leadiant Biosciences, Inc. | 1 | $28 |
| Nxstage Medical, Inc. | 2 | $27 |
| Abiomed | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,519 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 44 | $136,836 |
| FarxigaDapagliflozin Propanediol | 86 | $52,692 |
| JardianceEmpagliflozin | 64 | $42,618 |
| KerendiaFinerenone | 44 | $41,743 |
| AuryxiaFerric Citrate | 12 | $29,449 |
| RayaldeeCalcifediol | 12 | $14,560 |
| Sevelamer Carbonate | 56 | $14,014 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $6,934 |
| Midodrine Hcl | 29 | $3,922 |
| Calcitriol | 254 | $3,034 |
| Potassium Chloride | 153 | $1,753 |
| ClinisolParenteral Amino Acid 15% No.5 | 13 | $1,720 |
| Nifedipine ErNifedipine | 80 | $1,476 |
| Torsemide | 73 | $1,473 |
| Furosemide | 378 | $1,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $268 | $136,83644 claims |
| AstraZenecaFarxiga, Lokelma | $618 | $59,626105 claims |
| Boehringer IngelheimJardiance | $86 | $42,61864 claims |
| BayerKerendia | $654 | $41,74344 claims |
| Akebia Therapeutics IncAuryxia | $144 | $29,44912 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $151 | $14,56012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Zanesville
- Carrie AndrewsZanesville$17K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.